Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Holding STTK?
Track your performance easily
STTK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $11.76
Previous CloseN/A
Volume43.14K
Average Volume (3M)165.26K
Market Cap
$55.38M
Enterprise Value$90.97M
Total Cash (Recent Filing)$60.38M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.71
Next Earnings
Mar 18, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding47,739,708
10 Day Avg. Volume97,897
30 Day Avg. Volume165,264
Standard Deviation0.46
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.61
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/Revenue14.14
Enterprise Value/Gross Profit54.90
Enterprise Value/Ebitda-1.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering3
Shattuck Labs News
PremiumCompany Announcements
Shattuck Labs Focuses on Promising Antibody Development
Bulls Say, Bears Say
Bulls Say
Financial StabilityShattuck ended the quarter with $90.1 million in cash, which management believes provides runway for all ongoing operations into 2027.
Innovative Drug DevelopmentThe company is developing an early pipeline of potentially first-in-class DR3 mono- and bi-specific antibodies in IBD and other autoimmune diseases.
Strategic FocusThe company is focusing its efforts on the preclinical development of its recently announced lead asset, SL-325.
Bears Say
Competitive LandscapeIBD is a competitive space with ≥7 TL1A targeting programs in clinical/preclinical development.
Program DiscontinuationSTTK has discontinued the SL-172154 program in HR-MDS/AML based on uncompelling OS separation vs. historical controls.
Workforce ReductionManagement announced a significant restructuring including a 40% workforce reduction and a pivot into autoimmunity with its newly unveiled anti-DR3 mAb programs including SL-325.
---
Ownership Overview
19.12% Insiders
12.86% Mutual Funds
35.25% Other Institutional Investors
24.43% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
STTK FAQ
What was Shattuck Labs’s price range in the past 12 months?
Shattuck Labs lowest stock price was $0.94 and its highest was $11.76 in the past 12 months.
What is Shattuck Labs’s market cap?
Shattuck Labs’s market cap is $55.38M.
When is Shattuck Labs’s upcoming earnings report date?
Shattuck Labs’s upcoming earnings report date is Mar 18, 2025 which is in 46 days.
How were Shattuck Labs’s earnings last quarter?
Shattuck Labs released its earnings results on Nov 14, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.417 by $0.087.
Is Shattuck Labs overvalued?
According to Wall Street analysts Shattuck Labs’s price is currently Overvalued.
Does Shattuck Labs pay dividends?
Shattuck Labs does not currently pay dividends.
What is Shattuck Labs’s EPS estimate?
Shattuck Labs’s EPS estimate is -0.32.
How many shares outstanding does Shattuck Labs have?
Shattuck Labs has 47,739,708 shares outstanding.
What happened to Shattuck Labs’s price movement after its last earnings report?
Shattuck Labs reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.417. Following the earnings report the stock price went up 12.295%.
Which hedge fund is a major shareholder of Shattuck Labs?
Currently, no hedge funds are holding shares in STTK
---
Shattuck Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
STTK Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.24%
12-Months-Change
Fundamentals
Return on Equity
-71.09%
Trailing 12-Months
Asset Growth
-14.36%
Trailing 12-Months
Company Description
Shattuck Labs
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. The company's product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
---
STTK Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering STTK
1 Year
1 Year Success Rate
1/7 ratings generated profit
1 Year Average Return
-48.10%
assigned a buy rating 3 months ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -48.10% per trade.
---